Citations

Showing 10 of 108104 citations.

MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets
Swearson, Samuel , Rataan, Aseel O. , Eliason, Steven, Amendt, Brad A. , Zakharia, Yousef , Salem, Aliasger K. , Ho, Thai H. , Rustum, Youcef M. , Ho, Thai , Salem, Aliasger K , Zakharia, Yousef

Mayo Clinic

International Journal of Molecular Sciences | May 17, 2022 | Volume: 23 | Issue: 10 | Pages: 5604

10.3390/ijms23105604 | PMID 35628416 Get It

This study was carried out to quantitate the expression levels of microRNA-17, -19a, -34a, -155, and -210 (miRs) expressed in nine clear cell renal cell carcinoma (ccRCC) and one chromophobe renal cell carcinoma cell line with and without sarcomatoid differentiation, and in six primary kidney tumors with matching normal kidney tissues. The data in the five non-sarcomatoid ccRCC cell lines—RC2, CAKI-1, 786-0, RCC4, and RCC4/VHL—and in the four ccRCC with sarcomatoid differentiation—RCJ41T1, RCJ41T2, RCJ41M, and UOK-127—indicated that miR-17 and -19a were expressed at lower levels relative to miR-34a, -155, and -210. Compared with RPTEC normal epithelial cells, miR-34a, miR-155, and miR-210 were expressed at higher levels, independent of the sarcomatoid differentiation status and hypoxia-inducible factors 1α and 2α (HIFs) isoform expression. In the one chromophobe renal cell carcinoma cell line, namely, UOK-276 with sarcomatoid differentiation, and expressing tumor suppressor gene TP53, miR-34a, which is a tumor suppressor gene, was expressed at higher levels than miR-210, -155, -17, and -19a. The pilot results generated in six tumor biopsies with matching normal kidney tissues indicated that while the expression of miR-17 and -19a were similar to the normal tissue expression profile, miR-210, -155, -and 34a were expressed at a higher level. To confirm that differences in the expression levels of the five miRs in the six tumor biopsies were statistically significant, the acquisition of a larger sample size is required. Data previously generated in ccRCC cell lines demonstrating that miR-210, miR-155, and HIFs are druggable targets using a defined dose and schedule of selenium-containing molecules support the concept that simultaneous and concurrent downregulation of miR-210, miR-155, and HIFs, which regulate target genes associated with increased tumor angiogenesis and drug resistance, may offer the potential for the development of a novel mechanism-based strategy for the treatment of patients with advanced ccRCC.
Diabetes Rescue, Engagement and Management (D-REM): rationale and design of a pragmatic clinical trial of a community paramedicine programme to improve diabetes care
Juntunen, Michael B. , Liedl, Chad P., Carlson, Peter N., Stickler, Zachary R., Schultz, Jill A Ryan, MEILANDER, ANGELA K., Behnken, Emma , Rogerson, M Carson, Myers, Lucas A. , Ryan Schultz, Jill A, Lampman, Michelle A. , McCoy, Rozalina Grubina , Schultz, Jill Ryan, Fischer, Karen M. , McCoy, Rozalina G.

Mayo Clinic

BMJ Open | May 17, 2022 | Volume: 12 | Issue: 4 | Pages: e057224

10.1136/bmjopen-2021-057224 | PMID 35450906 Get It

Introduction Diabetes is one of the most common serious chronic health conditions in the USA. People living with diabetes face multiple barriers to optimal diabetes care, including gaps in access to medical care and self-management education, diabetes distress, and high burden of treatment. Community paramedics (CPs) are uniquely positioned to support multidisciplinary care for patients with diabetes by delivering focused diabetes self-management education and support and bridging the gaps between patients and the clinical and community resources they need to live well with their disease. Methods and analysis We will conduct a pragmatic single-arm prospective trial of a CP-led Diabetes Rescue, Engagement and Management (D-REM) programme that seeks to reduce diabetes distress. We will enrol 70 adults (≥18 years) with diabetes who have haemoglobin A1c (HbA1c)≥9.0%, experienced an emergency department (ED) visit or hospitalisation for any cause within the prior 6 months, and reside in areas with available CP support in Southeast Minnesota (Olmsted, Freeborn and Mower counties) and Northwest Wisconsin (Barron, Rusk and Dunn counties). Participants will be identified using Mayo Clinic electronic health records, contacted for consent and enrolled into the D-REM programme. Visit frequency will be individualised for each patient, but will be an average of four CP visits over the course of approximately 1 month. Outcomes will be change in diabetes distress (primary outcome), confidence in diabetes self-management, health-related quality of life, self-reported hypoglycaemia and hyperglycaemia, HbA1c, ED visits and hospitalisations. Outcomes will be assessed on enrolment, programme completion and 3 months after programme completion. Ethics and dissemination The study was approved by Mayo Clinic Institutional Review Board. Findings will be disseminated through peer-reviewed publications and presentations. If demonstrated to be successful, this model of care can be implemented across diverse settings and populations to support patients living with diabetes. Trial registration number NCT04385758 .
Real-world performance, long-term efficacy, and absence of bias in the artificial intelligence enhanced electrocardiogram to detect left ventricular systolic dysfunction
Harmon, David , Carter, Rickey E. , Cohen-Shelly, Michal , Svatikova, Anna , Adedinsewo, Demilade , Noseworthy, Peter A. , López-Jiménez, Francisco , Friedman, Paul A. , Attia, Zachi I. , Harmon, David M , Cohen-Shelly, Michal , Adedinsewo, Demilade A , Kapa, Suraj , Lopez-Jimenez, Francisco , Friedman, Paul A , Attia, Zachi I , Noseworthy, Peter A , Carter, Rickey E , Kapa, Suraj

Mayo Clinic

European Heart Journal - Digital Health | May 17, 2022 | Volume: 3 | Issue: 2 | Pages: 238-244

10.1093/ehjdh/ztac028 | PMID 36247412 Get It

Abstract Aims Some artificial intelligence models applied in medical practice require ongoing retraining, introduce unintended racial bias, or have variable performance among different subgroups of patients. We assessed the real-world performance of the artificial intelligence-enhanced electrocardiogram to detect left ventricular systolic dysfunction with respect to multiple patient and electrocardiogram variables to determine the algorithm’s long-term efficacy and potential bias in the absence of retraining. Methods and results Electrocardiograms acquired in 2019 at Mayo Clinic in Minnesota, Arizona, and Florida with an echocardiogram performed within 14 days were analyzed (n = 44 986 unique patients). The area under the curve (AUC) was calculated to evaluate performance of the algorithm among age groups, racial and ethnic groups, patient encounter location, electrocardiogram features, and over time. The artificial intelligence-enhanced electrocardiogram to detect left ventricular systolic dysfunction had an AUC of 0.903 for the total cohort. Time series analysis of the model validated its temporal stability. Areas under the curve were similar for all racial and ethnic groups (0.90–0.92) with minimal performance difference between sexes. Patients with a ‘normal sinus rhythm’ electrocardiogram (n = 37 047) exhibited an AUC of 0.91. All other electrocardiogram features had areas under the curve between 0.79 and 0.91, with the lowest performance occurring in the left bundle branch block group (0.79). Conclusion The artificial intelligence-enhanced electrocardiogram to detect left ventricular systolic dysfunction is stable over time in the absence of retraining and robust with respect to multiple variables including time, patient race, and electrocardiogram features.
Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy
Davidson, Tara M. , Foster, Nathan R. , Orme, Jacob J. , Orme, Jacob J , Lucien, Fabrice , Markovic, Svetomir N. , Dong, Haidong , Winters, Jeffrey L. , Park, Sean S.

Mayo Clinic

BMJ Open | May 17, 2022 | Volume: 12 | Issue: 5 | Pages: e050112

10.1136/bmjopen-2021-050112 | PMID 35551087 Get It

Background Patients with metastatic melanoma rely on PD-(L)1 immunotherapy, but only one-third of patients experience treatment response and all initial responders eventually develop resistance. Tumour-derived extracellular vesicles expressing Programmed death ligand 1 (evPD-L1) and soluble Programmed death ligand 1 (sPD-L1) in peripheral blood of patients with melanoma limit PD-(L)1 immunotherapy and correlate with poor survival. Therapeutic plasma exchange (TPE) removes immunosuppressive evPD-L1 and sPD-L1. We hypothesise that TPE may rescue and restore antimelanoma immunity. Methods In this two-arm study, 60 patients with metastatic melanoma progressing on checkpoint inhibition will be accrued. All patients will undergo radiotherapy on days 1–5 (at least one measurable lesion will not be irradiated) and ongoing checkpoint inhibition on day 8 and every 2–3 weeks per standard of care. Patients with baseline sPD-L1 level of ≥1.7 ng/mL and adequate clinical capacity will be enrolled in the TPE intervention arm and will undergo TPE on days 5–7, in addition to standard of care radiotherapy and immunotherapy. Other patients will remain in the standard of care arm. The primary endpoint of the study is to evaluate safety. Secondary endpoints include kinetics of sPD-L1 and evPD-L1 and clinical response by RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Study registered at ClinicalTrials.gov ( NCT04581382 ). Ethics and dissemination This trial has been approved by the Mayo Clinic Institutional Review Board. It will assess the safety and feasibility of TPE in improving outcomes for PD-(L)1 inhibitor immunotherapy in melanoma. Data will be maintained on a secure database with deidentified patient information. Data will be shared on publication in a peer-reviewed journal without the aid of professional writers. If successful, this trial will lay the ground for phase II studies that will include cancer treated with PD-(L)1 inhibitors which may benefit from TPE such as renal, bladder and lung cancers. Trial registration number NCT04581382 .
Hepatology highlights
Alva‐Ruiz, Roberto, Wu, Tiffany , Idalsoaga, Francisco , Ramkissoon, Resham­ , Wu, Tiffany , Arab, Juan Pablo , Ilyas, Sumera I.

Mayo Clinic

Hepatology | May 17, 2022 | Volume: 75 | Issue: 6 | Pages: 1363-1364

10.1002/hep.32524 Get It

How I approach smoldering multiple myeloma
Gertz, Morie A. , Gertz, Morie A , Vaxman, Iuliana

Mayo Clinic

Blood | May 16, 2022 | Volume: 140 | Issue: 8 | Pages: 828-838

10.1182/blood.2021011670 | PMID 35576526 Get It

Abstract The current standard of care in smoldering multiple myeloma (SMM) is close surveillance, outside of clinical trials. Efforts are being made to understand the pathobiologic process that leads to the progression of SMM to active MM. This review provides a critical description of available data, including risk factors and risk models of progression, as well as clinical trials investigating interventions for this patient population. We describe 2 cases in which patients were seen before the concept of a myeloma-defining event was established. Today, based on the International Myeloma Working Group criteria, both patients would have been identified as experiencing myeloma-defining events, and therapy would have been initiated. These cases show that occasionally, patients can undergo observation only, even when they exceed criteria for high-risk SMM.
Evaluation of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies Through Semiquantitative and Quantitative Analysis of Lung Computed Tomography
Roncella, Claudia , Valentini, Adele , Castellana, Roberto , Cioffi, Elisa, Tripoli, Alessandra, Biglia, Alessandro, Bartholmai, Brian J. , Liperi, Annalisa De, Bartholmai, Brian, Bartholmai, Brian J , Barsotti, Simone , Cavagna, Lorenzo , Zanframundo, Giovanni , Biglia, Alessandro , Mosca, Marta , Romei, Chiara

Mayo Clinic

Journal of Thoracic Imaging | May 16, 2022 | Volume: 37 | Issue: 5 | Pages: 344-351

10.1097/rti.0000000000000659 | PMID 35576535 Get It

Purpose: To perform a semiquantitative and quantitative analysis of interstitial lung disease (ILD), through computed tomography (CT), in different serological subgroups of idiopathic inflammatory myopathies (IIM) patients, to find radiologic and clinical differences of disease related to serology. Materials and Methods: This was a prospective study, which included 98 IIM patients, divided into serological subgroups: anti-aminoacyl-transfer-RNA-synthetases (anti-ARS) positive and myositis-specific autoantibodies (MSA) negative. For each baseline CT the total semiquantitative score of Warrick (WS) and the automated software (Computer-Aided Lung Informatics for Pathology Evaluation and Rating) quantitative scores interstitial lung disease % (ILD%) and vascular-related structure % (VRS%) were calculated. Pulmonary function tests included total lung capacity % (TLC%), forced vital capacity % (FVC%), and diffusing capacity of the lung for carbon monoxide % (DLCO%). Results: Inverse correlations (P<0.001) between the radiologic scores and the functional scores DLCO% and TLC% were found, the most relevant being between ILD% and DLCO% (ρ=−0.590), VRS% and DLCO% (ρ=−0.549), and WS and DLCO% (ρ=−0.471). Positive correlations between ILD% and VRS% (ρ=0.916; P<0.001), WS and ILD% (ρ=0.663; ρ<0.001), and WS and VRS% (ρ=0.637; P<0.001) were obtained. Statistically significant higher values of WS, ILD%, and VRS% were found in the anti-ARS group (WS=15; ILD%=11; VRS%=3.5) compared with the MSA negative one (WS=2.5; ILD%=0.84; VRS%=2.2). The nonspecific interstitial pneumonia pattern was dominant. No statistically significant differences emerged at pulmonary function tests. Conclusions: In this study, ILD in anti-ARS-positive and MSA-negative groups was defined through semiquantitative and quantitative analysis of lung CT. The inverse correlations between the radiologic scores and TLC% and DLCO% (P<0.001) confirm the role of lung CT in the evaluation of ILD in IIM.
The genomic and proteomic landscape in oral lichen planus versus oral squamous cell carcinoma: a scoping review
Xie, Fangyi , Meves, Alexander , Lehman, Julia S. , Lehman, Julia S

Mayo Clinic

International Journal of Dermatology | May 16, 2022 | Volume: 61 | Issue: 10 | Pages: 1227-1236

10.1111/ijd.16273 | PMID 35575880 Get It

AbstractBackgroundOral lichen planus (OLP), a World Health Organization (WHO)‐classified oral potentially malignant condition, confers a 1% risk of transformation to oral squamous cell carcinoma (OSCC). There does not appear to be a consensus understanding of the underlying molecular events. This scoping review aimed to identify critical molecular pathways and highlight gaps in existing knowledge on malignant transformation in OLP.MethodsFollowing Preferred Reporting Items for Systematic Reviews and Meta‐Analysis Protocols (PRISMA‐P) guidelines, a comprehensive literature search and methodical screening identified 61 relevant studies detailing molecular differences between OLP and OSCC.ResultsMolecular changes shared between OLP and OSCC included those affecting cellular proliferation (altered p53 expression, hypermethylation of p16/CDKN2A, MYC gains, increased ki‐67), apoptosis (increased bcl‐2 and survivin expression), extracellular matrix (ECM) remodeling (increased matrix metalloproteinase [MMP] expression), and transcriptional control (altered bmi1 and microRNA [miRNA] expression). In addition, some molecular alterations accumulated incrementally from control to OLP to OSCC or were present in higher‐risk erosive variants of OLP or transformed OLP. Few studies included rigorous diagnostic inclusion criteria or unbiased discovery methods.ConclusionsResults of this review support the potentially malignant nature of OLP and imply that molecular events associated with malignant transformation may be heterogeneous. In addition, findings in this review highlight the need for additional studies using rigorous diagnostic inclusion criteria and unbiased discovery methods to further understand this process.
Sarcoidosis-associated renal AA amyloidosis and crescentic necrotizing glomerulonephritis
Bui, Albert , Cortese, Cherise , Aslam, Nabeel

Mayo Clinic

Baylor University Medical Center Proceedings | May 16, 2022 | Volume: 35 | Issue: 5 | Pages: 680-682

10.1080/08998280.2022.2072163 | PMID 35991711 Get It

Cutaneous manifestations of ANCA‐associated vasculitis: a retrospective review of 211 cases with emphasis on clinicopathologic correlation and ANCA status
Shakshouk, Hadir , Gibson, Lawrence E. , Shakshouk, H

Mayo Clinic

International Journal of Dermatology | May 16, 2022 | Volume: 62 | Issue: 2 | Pages: 231-238

10.1111/ijd.16214 | PMID 35576100 Get It

AbstractBackgroundANCA‐associated vasculitis (AAV) may present a wide array of dermatological manifestations. Patients may remain ANCA negative, rendering diagnosis challenging for dermatologists if they depend heavily on ANCA testing to either confirm or rule out AAV.ObjectiveTo compare clinical and histopathological features of AAV patients with skin lesions who are ANCA positive versus those who are ANCA negative.MethodsRetrospective review of medical charts to identify patients diagnosed with AAV by clinical and pathologic criteria who also had cutaneous manifestations.ResultsSearch revealed that 211 out of 932 (23%) patients had cutaneous manifestations. Of those, 40/211 (20%) patients had persistently ANCA‐negative serology. Eosinophilic granulomatosis with polyangiitis (EGPA) comprised the largest cohort. Palpable purpura was the most prominent clinical feature. The most common histopathological feature was leukocytoclastic vasculitis (LCV) in 19 (29%) specimens, extravascular granuloma in 14 (22%), followed by perivascular infiltrate in 12 (18%), with eosinophils in nine. In the ANCA‐negative subgroup, perivascular infiltrate was more common followed by LCV but without statistically significant difference.ConclusionsDiagnosis of AAV should not be based on ANCA testing alone since a considerable number of patients with cutaneous lesions may be ANCA negative. The clinical or histopathologic findings of skin lesions in this study group did not vary based on ANCA status.